Rising Concerns Over FDA Consistency, Transparency: Axios
An Axios report examines growing criticism of recent FDA actions that are fueling uncertainty among drug developers and weakening public confidence in the agency. The article notes that top Trump-era health officials entered office arguing that the FDA lacked transparency, was overly influenced by industry, and failed to follow the best science. Those critiques, Axios reports, have only intensified in recent months.
Recent high-profile events — including the departure of CDER chief George Tidmarsh amid corruption allegations he denies — have reignited scrutiny of the agency’s decision-making. Other actions, such as removing Boxed Warnings from hormone therapies, advancing a new pathway for single-patient gene-editing products, and early steps toward approving a treatment for autism symptoms, have drawn pushback from experts and watchdog groups who say the agency appears to be deviating from traditional regulatory norms.
Analysts cited by Axios argue that inconsistent standards and public-facing policymaking have created unpredictability for drug sponsors and investors. They’ve created an environment where there’s increased uncertainty that’s jeopardizing investment and future innovations,” said Raymond James’ Chris Meekins, a former HHS official.
A former FDA official told Axios that recent moves “seem to be an interest in trying to get things done through the least amount of process,” contributing to perceptions that the agency is improvising its standards.
Public Citizen’s Robert Steinbrook added that while the FDA has historically been criticized for being slow, its reliance on multiple robust trials and transparent scientific debate has been core to maintaining credibility. Recent public-messaging-first approaches, he said, “do not inspire confidence.” The Wall Street Journal recently echoed similar concerns, accusing the agency of “arbitrary and shifting standards” in certain rare-disease reviews, Axios notes.
HHS rejected the criticism, telling Axios that “no FDA in history has produced so much regulatory innovation in such a short span,” and dismissed the report as unable to “keep up with the intellectual rigor that embodies today’s FDA.”